Levels of expression of complement regulatory proteins CD46, CD55 and CD59 on resting and activated human peripheral blood leucocytes

Immunology

Volumn 119, Issue 4, 2006, Pages 522-528

  Christmas, Stephen E ^a,b   De La Mata Espinosa, Claudia T ^a   Halliday, Deborah ^a   Buxton, Cheryl A ^a   Cummerson, Joanne A ^a   Johnson, Peter M ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

CD46; CD55; CD59; Leucocytes; Monocytes

Indexed keywords

CD59 ANTIGEN; DECAY ACCELERATING FACTOR; HEMAGGLUTININ; INTERLEUKIN 2 RECEPTOR ALPHA; LIPOPOLYSACCHARIDE; MEMBRANE COFACTOR PROTEIN;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CELL ISOLATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKOCYTE; MALE; MONOCYTE; NATURAL KILLER CELL; NEUTROPHIL; NORMAL HUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; UPREGULATION;

ADULT; ANTIGENS, CD46; ANTIGENS, CD55; ANTIGENS, CD59; CELL SEPARATION; CELLS, CULTURED; CENTRIFUGATION, DENSITY GRADIENT; COMPLEMENT INACTIVATOR PROTEINS; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; MONOCYTES; PHYTOHEMAGGLUTININS; UP-REGULATION;

EID: 33750879577     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2006.02467.x     Document Type: Article

References (37)

1. Longhi MP, Harris CL, Morgan BP, Gallimore A. Holding T cells in check - a new role for complement regulators? Trends Immunol 2006; 7:102-8.
2. Zaffran Y, Destaing O, Roux A, Ory S, Nheu T, Jurdic P, Rabourdin-Combe C, Astier AL. CD46/CD3 costimulation induces morphological changes of human T cells and activation of Vav, Rac, and extracellular signal-regulated kinase mitogen-activated protein kinase. J Immunol 2001; 167:6780-5.
3. Marie JC, Astier AL, Rivailler P, Rabourdin-Combe C, Wild TF, Horvat B. Linking innate and acquired immunity. Divergent role of CD46 cytoplasmicdomains in T cell induced inflammation. Nat Immunol 2002; 3:659-66.
4. + cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature 2003; 421:388-92.
5. + T cells by streptococcal M protein. J Immunol 2005; 175:677-84.
6. Kurita-Taniguchi M, Fukui A, Hazeki K et al. Functional modulation of human macrophages through CD46 (measles virus receptor). production of IL-12 p40 and nitric oxide in association with recruitment of protein-tyrosine phosphatase SHP-1 to CD46. J Immunol 2000; 165:5143-52.
7. Elward K, Griffiths M, Mizuno M, Harris CL, Neal JW, Morgan BP, Gasque P. CD46 plays a key role in tailoring innate immune recognition of apoptotic andnecrotic cells. J Biol Chem 2005; 280:36342-54.
8. Heeger PS, Lalli PN, Lin F, Valujskikh A, Liu J, Muqim N, Xu Y, Medof ME. Decay-accelerating factor modulates induction of T cell immunity. J Exp Med 2005; 201:1523-30.
9. Liu J, Miwa T, Hilliard B, Chen Y, Lambris JD, Wells AD, Song WC. The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo. J Exp Med 2005; 201:567-77.
10. Hamann J, Vogel B, van Schijndel GM, van Lier RA. The seven-span transmembrane receptor CD97 has a cellular ligand (CD55, DAF). J Exp Med 1996; 184:1185-9.
11. Lawrence DW, Bruyninckx WJ, Louis NA, Lublin DM, Stahl GL, Parkos CA, Colgan SP. Antiadhesive role of apical decay-accelerating factor (CD55) in human neutrophil transmigration across mucosal epithelia. J Exp Med 2003; 198:999-1010.
12. Tausk F, Fey M, Gigli I. Endocytosis and shedding of the decay accelerating factor on human polymorphonuclear cells. J Immunol 1989; 143:3295-302.
13. Jones J, Morgan BP. Apoptosis is associated with reduced expression of complement regulatory molecules, adhesion molecules and other receptors on polymorphonuclear leucocytes. functional relevance and role in inflammation. Immunology 1995; 86:651-60.
14. Berger M, Medof ME. Increased expression of complement decay-accelerating factor during activation of human neutrophils. J Clin Invest 1987; 79:214-20.
15. Naderi S, Hofmann P, Seiter S, Tilgen W, Abken H, Reinhold U. CD2-mediated CD59 stimulation in keratinocytes results in secretion of IL-1alpha, IL-6, and GM-CSF. implications for the interaction of keratinocytes with intraepidermal T lymphocytes. Int J Mol Med 1999; 3:609-14.
16. Yamamoto T, Nakane T, Doi S, Osaki T. Lipopolysaccharide signal transduction in oral keratinocytes - involvement of CD59 but not CD14. Cell Signal 2003; 15:861-9.
17. Marcenaro E, Augugliaro R, Falco M et al. CD59 is physically and functionally associated with natural cytotoxicity receptors and activates human NK cell-mediated cytotoxicity. Eur J Immunol 2003; 33:3367-76.
18. Deckert M, Kubar J, Bernard A. CD58 and CD59 molecules exhibit potentializing effects in T cell adhesion and activation. J Immunol 1992; 148:672-7.
19. Omidvar N, Wang EC, Brennan P, Longhi MP, Smith RA, Morgan BP. Expression of glycosylphosphatidylinositol-anchored CD59 on target cells enhances human NK cell-mediated cytotoxicity. J Immunol 2006; 176:2915-23.
20. Ghiran I, Klickstein LB, Nicholson-Weller A. Calreticulin is at the surface of circulating neutrophils and uses CD59 as an adaptor molecule. J Biol Chem 2003; 278:21024-31.
21. Monleon I, Martinez-Lorenzo MJ, Anel A, Lasierra P, Larrad L, Pineiro A, Naval J, Alava MA. CD59 cross-linking induces secretion of APO2 ligand in overactivated human T cells. Eur J Immunol 2000; 30:1078-87.
22. Terstappen LW, Nguyen M, Lazarus HM, Medof ME. Expression of the DAF (CD55) and CD59 antigens during normal hematopoietic cell differentiation. J Leukoc Biol 1992; 52:652-60.
23. - lymphocytes (NK cells). Cell Immunol 1995; 165:294-301.
24. Cui W, Fan Y, Yang M, Zhang Z. Expression of CD59 on lymphocyte and the subsets and its potential clinical application for paroxysmal nocturnal hemoglobinuria diagnosis. Clin Lab Haematol 2004; 26:95-100.
25. Moutabarrik A, Nakanishi I, Namiki M et al. Cytokine-mediated regulation of the surface expression of complement regulatory proteins, CD46 (MCP), CD55 (DAF), and CD59 on human vascular endothelial cells. Lymphokine Cytokine Res 1993; 12:167-72.
26. Beutler B. TLR4 as the mammalian endotoxin sensor. Curr Top Microbiol Immunol 2002; 270:109-20.
27. Heine H, El-Samalouti VT, Notzel C et al. CD55/decay accelerating factor is part of the lipopolysaccharide-induced receptor complex. Eur J Immunol 2003; 33:1399-408.
28. MacPherson GG, Pugh CW. Heterogeneity amongst lymph-borne 'dendritic' cells. Immunobiology 1984; 168:338-48.
29. Bryant RW, Granzow CA, Siegel MI, Egan RW, Billah MM. Wheat germ agglutinin and other selected lectins increase synthesis of decay-accelerating factor in human endothelial cells. J Immunol 1991; 147:1856-62.
30. Chakrabarti R, Jung CY, Lee TP, Liu H, Mookerjee BK. Changes in glucose transport and transporter isoforms during the activation of human peripheral blood lymphocytes by phytohemagglutinin. J Immunol 1994; 152:2660-8.
31. Ohashi Y, Takeshita T, Nagata K, Mori S, Sugamura K. Differential expression of the IL-2 receptor subunits, p55 and p75 on various populations of primary peripheral blood mononuclear cells. J Immunol 1989; 143:3548-55.
32. Valitutti S, Carbone A, Castellino F, Maggiano N, Ricci R, Larocca LM, Musiani P. The expression of functional IL-2 receptor on activated macrophages depends on the stimulus applied. Immunology 1989; 67:44-50.
33. Mason JC, Yarwood H, Sugars K, Morgan BP, Davies KA, Haskard DO. Induction of decay-accelerating factor by cytokines or the membrane-attack complex protects vascular endothelial cells against complement deposition. Blood 1999; 94:1673-82.
34. Cocuzzi ET, Bardenstein DS, Stavitsky A, Sundarraj N, Medof ME. Upregulation of DAF (CD55) on orbital fibroblasts by cytokines. Differential effects of TNF-beta and TNF-alpha. Curr Eye Res 2001; 23:86-92.
35. Cattaneo R. Four viruses, two bacteria, and one receptor: membrane cofactor protein (CD46) as pathogens' magnet. J Virol 2004; 78:4385-8.
36. Smith LJ. Paroxysmal nocturnal hemoglobinuria. Clin Laboratory Sci 2004; 17:172-7.
37. Jones J, Laffafian I, Cooper AM, Williams BD, Morgan BP. Expression of complement regulatory molecules and other surface markers on neutrophils from synovial fluid and blood of patients with rheumatoid arthritis. Br J Rheumatol 1994; 33:707-12.